CDTX NASDAQ
Cidara Therapeutics, Inc.
1W: +0.0%
1M: +0.5%
3M: +129.3%
1Y: +832.4%
3Y: +1525.4%
5Y: +423.4%
$221.38
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$1M
-98.0% ▼
5Y CAGR: -42.9%
Gross Profit
$1M
-234.0% ▼
Operating Income
-$176M
-619.3% ▼
Net Income
-$170M
-640.6% ▼
EPS (Diluted)
$-26.75
-409.5% ▼
EBITDA
-$176M
-622.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $12M | $50M | $64M | $23M | $1M |
| YoY Growth | -42.3% | +310.8% | +29.7% | -0.6% | -98.0% |
| Cost of Revenue | $0 | $73M | $0 | $37M | $0 |
| Gross Profit | $12M | -$24M | $64M | -$13M | $1M |
| Gross Margin | 100.0% | -47.4% | 100.0% | -57.9% | 100.0% |
| R&D Expenses | $68M | $73M | $77M | $37M | $157M |
| SG&A Expenses | $16M | $19M | $21M | $14M | $21M |
| Operating Expenses | $84M | $19M | $98M | $14M | $177M |
| Operating Income | -$72M | -$42M | -$34M | -$27M | -$176M |
| Operating Margin | -595.4% | -85.2% | -52.0% | -116.2% | -13811.9% |
| Interest Expense | $262K | $0 | $0 | $0 | $0 |
| Income Before Tax | -$72M | -$42M | -$33M | -$25M | -$170M |
| Tax Expense | $0 | $0 | $272K | $15K | $0 |
| Net Income | -$72M | -$42M | -$34M | -$23M | -$170M |
| Net Margin | -597.6% | -85.7% | -52.1% | -98.5% | -13319.8% |
| EPS (Diluted) | $-36.03 | $-16.19 | $-9.61 | $-5.25 | $-26.75 |
| EBITDA | -$71M | -$42M | -$33M | -$27M | -$176M |
| Shares Outstanding | 2M | 3M | 3M | 4M | 6M |